Grace Therapeutics, Inc.
GRCE
$3.00
-$0.13-4.15%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 120.09% | -73.78% | -4.86% | 34.95% | 89.12% |
| Total Depreciation and Amortization | 100.00% | 100.00% | 0.00% | -85.71% | -87.50% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1,045.31% | 9,262.50% | -162.39% | -849.49% | -98.53% |
| Change in Net Operating Assets | -109.38% | -237.35% | 143.75% | 144.42% | 99.43% |
| Cash from Operations | -41.48% | -117.49% | -100.62% | 42.37% | 37.22% |
| Capital Expenditure | -- | -- | -- | -- | -175.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -100.00% | 100.23% | -- | -- | 31.38% |
| Cash from Investing | -100.00% | 100.23% | -100.00% | -- | 31.17% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 9,158.64% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -496.91% | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 148.39% | 51.46% | -179.12% | 42.15% | 172.95% |